AN2 Therapeutics (NASDAQ: ANTX) insider transactions
In the twelve months to 10 November 2026, executives and directors of AN2 Therapeutics reported 21 open-market sales of 111,638 shares ($406,105) and 1 open-market purchase of 2,098 shares ($11,602), by 7 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 5 November 2026 | Eizen Joshua M | See Remarks | Open-market sale | −2,826 | $4.22 | 207,546 | Form 4 |
| 12 October 2026 | Aziz Kabeer | Director | Grant or award | +2,465 | — | 61,571 | Form 4 |
| 12 October 2026 | Martin Patricia A. | Director | Grant or award | +389 | — | 19,252 | Form 4 |
| 12 October 2026 | Marks Gilbert Lynn | Director | Grant or award | +2,283 | — | 84,156 | Form 4 |
| 15 September 2026 | Trenor Cameron C. III | Chief Medical Officer | Grant or award | +116,667 | — | 116,667 | Form 4 |
| 9 September 2026 | Readnour Robin Shane | Director | Open-market sale | −523 | $6.02 | 557,467 | Form 4 |
| 9 September 2026 | Readnour Robin Shane | Director | Open-market sale | −585 | $6.02 | 624,765 | Form 4 |
| 8 September 2026 | Readnour Robin Shane | Director | Open-market sale | −4,725 | $6.02 | 557,990 | Form 4 |
| 8 September 2026 | Readnour Robin Shane | Director | Open-market sale | −5,294 | $6.02 | 625,350 | Form 4 |
| 3 September 2026 | Readnour Robin Shane | Director | Open-market sale | −2,877 | $6.07 | 562,715 | Form 4 |
| 3 September 2026 | Readnour Robin Shane | Director | Open-market sale | −3,223 | $6.07 | 630,644 | Form 4 |
| 1 September 2026 | Williams Sarah Joanne | Principal Accounting Officer | Open-market sale | −272 | $5.53 | 66,311 | Form 4 |
| 1 September 2026 | FitzPatrick Margaret M | Director | Open-market purchase | +2,098 | $5.53 | 10,708 | Form 4 |
| 17 August 2026 | Readnour Robin Shane | Director | Open-market sale | −16,696 | $6.01 | 565,592 | Form 4 |
| 17 August 2026 | Readnour Robin Shane | Director | Open-market sale | −18,706 | $6.01 | 633,867 | Form 4 |
| 14 August 2026 | Zakrzewski Joseph S | Director | Gift | −405,880 | — | 0 | Form 4 |
| 10 July 2026 | Martin Patricia A. | Director | Grant or award | +766 | — | 18,863 | Form 4 |
| 10 July 2026 | Marks Gilbert Lynn | Director | Grant or award | +2,789 | — | 81,873 | Form 4 |
| 10 July 2026 | Aziz Kabeer | Director | Grant or award | +2,852 | — | 59,106 | Form 4 |
| 8 July 2026 | Eizen Joshua M | See Remarks | Open-market sale | −5,945 | $4.17 | 206,554 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the AN2 Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.